SCHEMBL9904567

SCHEMBL9904567

CCOC(=O)C1=C(c2ccc(C)cc2)C(=O)c2ccccc2C1=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.78
LMNA P02545 9/20 0.78
MEN1 O00255 9/20 0.78
KMT2A Q03164 9/20 0.78
ALDH1A1 P00352 9/20 0.78
NPSR1 Q6W5P4 8/20 0.78
KDM4E B2RXH2 7/20 0.78
SMN1; SMN2 Q16637 6/20 0.78
TDP1 Q9NUW8 6/20 0.78
HKDC1 Q2TB90 5/20 0.78
HTT P42858 4/20 0.78
HSP90AA1 P07900 4/20 0.78
MAPK1 P28482 3/20 0.78
L3MBTL1 Q9Y468 3/20 0.78
NPC1 O15118 2/20 0.78
MPI P34949 2/20 0.78
RAB9A P51151 2/20 0.78
TP53 P04637 1/20 0.78
HPGD P15428 6/20 0.65
ALOX12 P18054 4/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17969781 0.91 ALDH1A1 (0.78) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL13561203 0.89 HSP90AA1 (0.74) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL2489785 0.88 MAPT (1.00) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL7538581 0.85 PPARG (0.72) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3576647 0.80 PPARG (0.76) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL17969754 0.79 HSP90AA1 (0.57) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL5138606 0.79 ALDH1A1 (0.51) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL8285454 0.79 MAPT (1.00) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL17969759 0.79 MEN1 (0.59) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL8359086 0.79 PPARG (0.63) MAPTLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012079032-A2 COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS TRANA DISCOVERY, INC. (US) 2012-06-14 WO claimed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 US disclosed
WO-2012079032-A2 COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS TRANA DISCOVERY, INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 MAPT 3443/4885LMNA 2558/4885MEN1 4495/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MAPT 3443/4885LMNA 2558/4885MEN1 4495/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 MAPT 3443/4885LMNA 2558/4885MEN1 4495/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MAPT 3443/4885LMNA 2558/4885MEN1 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.